Cantor Fitzgerald raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $30 from $20 and keeps an Overweight rating on the shares. Rocket’s preliminary data for RP-A601, its Adeno-associated virus rhesus serotype 74 gene therapy in 3 patients with plakophilin-2-Arrhthmogenic Cardiomyopathy, are “very encouraging,” the analyst tells investors in a research note. PKP2 is a large unmet need, patients are broadly identified, current treatment options are subpar and the preliminary results for RP-A601 are very compelling, the firm argues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Promising Phase I Data and Strategic Focus Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals price target raised to $46 from $45 at Chardan
- Promising Developments and Strategic Advancements Make Rocket Pharmaceuticals a Compelling Buy
- Promising Clinical Data and Potential FDA Pathway Justify Buy Rating for Rocket Pharmaceuticals
- Promising Potential of Rocket Pharmaceuticals’ RP-A601: Buy Rating Justified by Encouraging Phase 1 Results and Advancements